CN109862905A - 用于治疗骨关节炎的肽 - Google Patents

用于治疗骨关节炎的肽 Download PDF

Info

Publication number
CN109862905A
CN109862905A CN201780042664.6A CN201780042664A CN109862905A CN 109862905 A CN109862905 A CN 109862905A CN 201780042664 A CN201780042664 A CN 201780042664A CN 109862905 A CN109862905 A CN 109862905A
Authority
CN
China
Prior art keywords
seq
ser
lys
peptide
asp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780042664.6A
Other languages
English (en)
Chinese (zh)
Inventor
克劳德·卡雷利
克里斯泰勒·韦图
拉法埃洛·保利尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regulaxis Co
Original Assignee
Regulaxis Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regulaxis Co filed Critical Regulaxis Co
Publication of CN109862905A publication Critical patent/CN109862905A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780042664.6A 2016-06-10 2017-06-09 用于治疗骨关节炎的肽 Pending CN109862905A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16174056.8 2016-06-10
EP16174056 2016-06-10
PCT/EP2017/064196 WO2017212057A1 (en) 2016-06-10 2017-06-09 Peptides for the treatment of osteoarthritis

Publications (1)

Publication Number Publication Date
CN109862905A true CN109862905A (zh) 2019-06-07

Family

ID=56132793

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780042664.6A Pending CN109862905A (zh) 2016-06-10 2017-06-09 用于治疗骨关节炎的肽

Country Status (12)

Country Link
US (1) US10813980B2 (cg-RX-API-DMAC7.html)
EP (1) EP3468582A1 (cg-RX-API-DMAC7.html)
JP (1) JP7010934B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190018466A (cg-RX-API-DMAC7.html)
CN (1) CN109862905A (cg-RX-API-DMAC7.html)
AU (1) AU2017277747A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018075613A2 (cg-RX-API-DMAC7.html)
CA (1) CA3026984A1 (cg-RX-API-DMAC7.html)
IL (1) IL263564B (cg-RX-API-DMAC7.html)
MA (1) MA45227A (cg-RX-API-DMAC7.html)
RU (1) RU2018145945A (cg-RX-API-DMAC7.html)
WO (1) WO2017212057A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108785661A (zh) * 2018-07-20 2018-11-13 深圳市第二人民医院 一种无副作用治疗退行性骨关节病的注射剂及其制备方法
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
KR102856432B1 (ko) 2022-02-23 2025-09-08 중앙대학교 산학협력단 졸참나무 잎 추출물을 유효성분으로 포함하는 골관절염 예방 또는 치료용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127402A1 (en) * 2002-12-27 2004-07-01 Vad Vijay B. Injectible composition and method for treating degenerative animal joints
US20040253723A1 (en) * 2003-02-28 2004-12-16 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20120135926A1 (en) * 2009-03-19 2012-05-31 Universite Pierre Et Marie Curie (Paris 6) Peptides for inhibiting igf-1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1208760B (it) * 1986-11-04 1989-07-10 Ind Farmaceutica Serono S P A Trattamento delle malattie infiammatorie articolari
FR2833012B1 (fr) 2001-12-04 2004-01-30 Centre Nat Rech Scient Peptides agonistes de l'hormone de croissance et leurs applications
US20070184015A1 (en) 2006-02-03 2007-08-09 Soonkap Hahn Novel PEGylation agent
EP2502632B1 (en) 2009-11-18 2016-12-28 Asahi Kasei Pharma Corporation Preventative agent and/or therapeutic agent and/or exacerbation-suppressing agent for human knee osteoarthritis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127402A1 (en) * 2002-12-27 2004-07-01 Vad Vijay B. Injectible composition and method for treating degenerative animal joints
US20040253723A1 (en) * 2003-02-28 2004-12-16 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20120135926A1 (en) * 2009-03-19 2012-05-31 Universite Pierre Et Marie Curie (Paris 6) Peptides for inhibiting igf-1

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
张丽雯等: "生长抑素治疗关节炎的临床研究", 《中国疼痛医学杂志》 *

Also Published As

Publication number Publication date
RU2018145945A (ru) 2020-07-10
EP3468582A1 (en) 2019-04-17
WO2017212057A1 (en) 2017-12-14
IL263564B (en) 2021-07-29
BR112018075613A2 (pt) 2019-04-09
US10813980B2 (en) 2020-10-27
JP7010934B2 (ja) 2022-02-10
RU2018145945A3 (cg-RX-API-DMAC7.html) 2020-07-10
JP2019522046A (ja) 2019-08-08
US20190298808A1 (en) 2019-10-03
MA45227A (fr) 2019-04-17
IL263564A (en) 2019-02-03
KR20190018466A (ko) 2019-02-22
CA3026984A1 (en) 2017-12-14
AU2017277747A1 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
JP5607176B2 (ja) 新規ペプチドおよびその用途
EP3208278B1 (en) Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use
JP2020196762A (ja) 熱傷及び二次性合併症の予防及び治療方法
RU2691946C2 (ru) Схема применения соединения fgf-18
JP6510547B2 (ja) Fgf−18を含むインプラント
KR20230066428A (ko) 미토콘드리아에 비오틴의 전달을 위한 방법 및 조성물
EP2897974B1 (en) Use of pedf-derived polypeptides for treating osteoarthritis
JP7010934B2 (ja) 変形性関節症の治療のためのペプチド
KR102012380B1 (ko) 골재생 또는 골형성 촉진용 펩타이드 및 그 용도
US20210145850A1 (en) Composition, for osteoarthritis treatment, comprising hydrophilized sulfasalazine and hyaluronic acid and method for preparing same
KR101736280B1 (ko) 관절염 예방 또는 치료용 약학적 조성물
EP3384923A1 (en) C4bp-based compounds for treating immunological diseases
CN107670021B (zh) 五胜肽kttks在治疗退化性关节炎中的用途
WO2025111563A1 (en) Milk peptide compositions for pharmaceutical and cosmeceutical use
BR112020012466A2 (pt) neurotoxinas para uso na minimização de cicatriz
CN110772632B (zh) 神经导向因子semaphorin 3a在制备治疗骨关节炎药物中的用途
CN107670020B (zh) 四胜肽gekg在治疗退化性关节炎中的用途
KR20180035911A (ko) Fgf-18 화합물을 포함하는 조합 조성물
TWI660735B (zh) 四/五胜肽gekg(f)於治療退化性關節炎之用途
KR102933203B1 (ko) 콜라겐 안정화제 조성물
US9637531B2 (en) Selective cartilage therapy
WO2025163204A1 (en) Glutamine source for use in methods and compositions for reducing or preventing synovial joint adhesions or fibrosis
Lynch et al. Miniglucagon and glucagon fragment peptides have differential effects on insulin secretion in cultured pancreatic beta cells
HK1231093A1 (en) Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use
US20190343915A1 (en) Peptides for therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190607

WD01 Invention patent application deemed withdrawn after publication